A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Clinical trial NCT06064890 · RECRUITING

Trial details

NCT number: NCT06064890
Sponsor: AviadoBio Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Frontotemporal Dementia FTD FTD-GRN Dementia, Frontotemporal

Start date: 2023-08-30
Primary completion: 2027-04-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.